Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Correction

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Authors: Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, Andrea Botticelli

Published in: BMC Cancer | Issue 1/2024

Login to get access

Excerpt

Correction: BMC Cancer 24, 430 (2024) …
Literature
1.
Metadata
Title
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
Authors
Alessio Cirillo
Daniele Marinelli
Umberto Romeo
Daniela Messineo
Francesca De Felice
Marco De Vincentiis
Valentino Valentini
Silvia Mezi
Filippo Valentini
Luca Vivona
Antonella Chiavassa
Bruna Cerbelli
Daniele Santini
Paolo Bossi
Antonella Polimeni
Paolo Marchetti
Andrea Botticelli
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12249-y

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Determination of drug-related problems in the hematology service: a prospective interventional study

Research

Reductive prodrug and AIE copolymer nanoparticle for monitoring and chemotherapy

Research

Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma

Correction

Correction: How should the healthcare system support cancer survivors? Survivors’ and health professionals’ expectations and perception on comprehensive cancer survivorship care in Korea: a qualitative study

Retraction Note

Retraction Note: Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells

Research

Carbon-ion radiotherapy for hepatocellular carcinoma with major vascular invasion: a retrospective cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits